Yesterday, the Food and Drug Administration's (FDA) advisory committee met to discuss Merck's (NYSE:MRK) experimental insomnia drug Suvorexant. While the committee did agree that the drug was effective at lower doses, there were some concerns over the side-effects associated with the medication at higher doses. In the following video, health-care analyst Max Macaluso discusses the results of the meeting, and how the ultimate FDA decision on Suvorexant can impact Merck's stock.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 57% 38%
17+ years 346% 95%
Stock Advisor launched in February of 2002. Returns as of 12/10/2019.Join Stock Advisor